Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many removals from elective waiting lists there have been as a result of data validation exercises in 2025-26; and what the cost to his Department has been of those exercises.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Validation is a well-established component for the effective management of waiting lists, ensuring that the patients who are on the list should still be there. While we have significantly reduced the size of the total elective waiting list by over 206,000 since the Government took office, a large list requires consistent validation in order to ensure that all patients on the list still require care, and all appointments are of optimum value for patients and clinicians.
The Department does not hold data centrally on the number of patient pathways removed from the elective waiting list as a result of data validation.
NHS England has paid the system £18,818,566 for validation exercises from April to September 2025. Payments for the most recent validation exercises have not yet been issued to providers. We know validation provides significant benefits for patients by reducing missed appointments, making effective use of clinical time, and ensuring patients are on the best care pathway for their needs.
Asked by: Alex Brewer (Liberal Democrat - North East Hampshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will include information in the Green Book on the HPV vaccine that includes reference to its role in reducing the risk of oral cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Green Book is written for healthcare professionals. The chapter on human papillomavirus (HPV) does highlight the causal link between infection with this virus, cervical cancer, and some non-cervical cancer including those of the head and neck. The HPV chapter 18a from the Green Book is available at the following link:
https://www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a
Broader UK Health Security Agency guidance on HPV also highlights the protection the vaccine provides against HPV infection and related conditions. This public‑facing information also explains that the vaccine helps protect against cancers of the mouth and is available at the following link:
It also highlights that the greatest risk comes from infection with high-risk types of HPV. There is very good evidence that the vaccine in use in the United Kingdom offers excellent protection against these high-risk types.
Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure that cancer patients in Newbury are treated within 62 days.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We have now exceeded our pledge to deliver an extra two million appointments across elective, diagnostic, and cancer care, having now delivered over five million more appointments as the first step to ensuring earlier and faster access to treatment.
Between November 2024 to October 2025, approximately 110,000 more patients were diagnosed or had cancer ruled out within 28 days compared to the previous 12 months. This supports the achievement of the 62-day treatment standard, as faster diagnosis means that patients can begin treatment sooner.
The latest available data shows that the 62-day treatment standard for the NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board has improved by 3.5% between October 2024 and October 2025.
However, we recognise that there is more to do, including for patients in Newbury.
To ensure that the most advanced treatment is available to the patients who need it, and so that patients can be treated sooner, the Government has also invested £70 million of central funding to replace outdated radiotherapy machines, including one at the Royal Berkshire Hospital.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he plans to take to increase (a) capacity of and (b) access to radiotherapy cancer treatment in (i) England and (ii) Stratford-upon-Avon.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Radiotherapy is crucial to cancer treatment, and it remains a key priority for the Government to reduce radiotherapy waiting times and provide high quality treatment for all patients, including those in Stratford-upon-Avon. This is why the Government has invested £70 million of central funding on 28 new LINAC radiotherapy machines across the country to replace older, less efficient radiotherapy machines. This crucial investment will boost treatment efficiency and productivity, freeing up capacity and reduce waiting times for patients. These new machines are currently being rolled out and have already started treating cancer patients across the country.
The Coventry and Warwickshire NHS Trust received £2.3 million to replace ageing radiotherapy equipment from an underspend in the National Health Service’s capital settlement for 2024/25.
Asked by: Julian Smith (Conservative - Skipton and Ripon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that local cancer treatment facilities, such as mobile chemotherapy units and hospital breast cancer clinics, have sufficient resources to meet demand and reduce waiting times for patients.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the plan for reforming elective care, the Government is committed to improving performance on cancer waiting times.
To improve access to cancer treatment, the Government is investing an extra £26 billion in the National Health Service and providing it with the resources it needs, including community diagnostic centres, to ensure patients are diagnosed faster and earlier so that they receive timely access to treatment. £70 million will also be spent on replacing out-of-date radiotherapy equipment so that cancer patients benefit from faster and safer cancer treatment using the most up-to-date technology. Replacing these older machines will save as many as 13,000 appointments from being lost to equipment breakdown.
NHS England has partnered with the charity Hope For Tomorrow to establish mobile chemotherapy units across England, bringing chemotherapy and cancer treatments closer to patients' homes, reducing waiting time for hospital appointments, with units staffed by specialist nurses offering personalised care.
The NHS has made important progress on the treatment of cancer, including breast cancer, delivering an extra 40,000 operations, scans, and appointments each week to ensure faster treatment for those who need it most.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many and what proportion of people eligible for winter flu vaccinations received them in 2025.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
For England, the UK Health Security Agency (UKHSA) publishes provisional vaccine uptake data throughout the flu season. Weekly national level data for general practice (GP) patients is available from October to January, at the following link:
Monthly national and regional level data for GP patients, school-aged children, and frontline healthcare workers (HCWs) is available from October to January. The latest monthly data for the 2025 to 2026 season includes all vaccinations given between 1 September to 30 November 2025, and is avaiable at the following link:
https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptake:-figures
Up to 4 January 2026, over 18 million people eligible for the national programme had been vaccinated so far this season.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 December 2025 to Question 95676, whether his Department has conducted any evaluation of patient safety risks affecting people with severe and very severe ME/CFS, including malnutrition.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Patient safety risks affecting people with severe and very severe myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), including malnutrition, have been considered during the development of the final delivery plan (FDP) published in July this year, through engagement with stakeholders, including clinicians and patient groups.
To this end, the FDP includes an action for the Department and NHS England to explore whether a specialised service should be prescribed by my Rt Hon. Friend, the Secretary of State for Health and Social Care, for very severe ME/CFS. Officials from the Department have commenced discussions with NHS England on how best to take forward this action.
Asked by: Jo White (Labour - Bassetlaw)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department will consider allowing families of vulnerable patients who are at highest risk, particularly those affected by transplants and kidney disease, access to NHS COVID vaccinations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The JCVI has advised that population immunity to COVID-19 has increased due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.
The JCVI has also advised that as currently available COVID-19 vaccines provide limited protection against transmission and mild or asymptomatic disease, the focus of the programme is on offering vaccination to those most likely to directly benefit from vaccination. These are the oldest adults and individuals who are immunosuppressed.
The Government has accepted the JCVI advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps the evidence under regular review.
Asked by: Liz Jarvis (Liberal Democrat - Eastleigh)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the availability and quality of data held by Integrated Care Boards on the prevalence of clinically diagnosed allergic conditions and the specialist allergy workforce in their local areas; and what consideration has he given to the potential merits of establishing a National Allergy Register, embedded within the planned Single Patient Record in improving patient safety and reducing regional inequalities in allergy care.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In conducting health needs assessments to inform their commissioning decisions, integrated care boards (ICBs) will have access to a wide range of data sources, including public health data, hospital statistics, primary care data, and social care metrics.
NHS England is working with the UK Fatal Anaphylaxis Register (UKFAR) to develop a mechanism for sharing relevant patient safety anaphylaxis incidents, including the reporting of anaphylaxis in hospitals. The aim will be for the UKFAR to extract and share patient safety incidents reported to the national databases, the National Reporting and Learning System and Learn from Patient Safety Events, relating to severe allergic reactions. Work has been progressing on this.
The National Allergy Strategy Group, an external group of stakeholders, is developing a UK National Allergy Strategy 2025-2035. The Department will carefully consider and respond to it when we receive it next year.
Asked by: Tom Hayes (Labour - Bournemouth East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to support paediatric settings to adopt the recommended Play Well standards in NHS England's Play Well toolkit published in June 2025.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises the importance of supporting and maintaining children’s right to play in healthcare settings.
The NHS England and Starlight Play Well Toolkit, published in June 2025, includes the first national guidelines and standards for commissioning and delivering health play services in England. It aims to improve access to child-friendly care and specialised health play services across paediatric healthcare.
To support adoption of Play Well standards, NHS England is promoting the toolkit to managers of health play services across a wide range of settings, including community clinics, emergency departments, children’s hospices, and acute paediatric wards. The toolkit provides clear guidance on supporting practical training and mentorship in healthcare settings.
A range of communication channels have been used to raise awareness, including engagement with services via professional bodies, messaging via the Chief Nursing Officer, a blog posts and ongoing promotion of the toolkit across the National Health Service through operational delivery networks, directly to trusts and directly with professional groups.